Immunalgia Therapeutics was created in 2019 by three renowned scientist from the National Scientific and Technical Research Council (CONICET) (Argentina) with complementary capabilities that include: a solid background in drug development, regulatory aspects, technology transfer and the study of pain and its potential treatments. The team is completed by a multidisciplinary group of experts in patents, pharmacology, clinical studies and financing.
In recent years it has been discovered that chronic pain, in addition to being processed by the nervous system and its neurons, develops together of glial cells and the immune system. The therapy proposed by Immunalgia Therapeutics has the virtue of alleviating pain, precisely by acting on these three components. Therein lies its innovative character and the real possibility of being taken to society to solve a problem for which there are currently no adequate treatments.